Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
OCULthis companyOcular Therapeutix, Inc.	$6.63	-8.55×	3.47×	43.86×	-6.47×	-101.4%	87.3%	-521.0%	-513.2%	-40.6%	-35.5%	-9.5%	0.12×	2.63×	-22.82×	15.39×	0.0%	2	2.82	1	C-
EYPTEyePoint Pharmaceuticals, Inc.	$0.35	-5.76×	4.37×	42.66×	-5.49×	-1218.8%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.09	1	C-
GKOSGlaukos Corporation	$235.47	-34.42×	9.84×	12.73×	-44.54×	-132.8%	77.5%	-17.1%	-37.0%	-28.6%	-10.6%	-0.8%	0.21×	-0.33×	-18.71×	4.69×	0.0%	4	31.48	1	C-
HROWHarrow Health, Inc.	$26.74	-350×	34.35×	6.61×	47×	-1507.5%	75.1%	14.2%	-1.9%	-9.8%	12.7%	2.4%	4.8×	4.25×	1.6×	2.2×	0.0%	4	1.85	1	C-
KODKodiak Sciences Inc.	$105.57	-6.47×	9.45×	0×	-7.06×	-99.2%	0.0%	0.0%	0.0%	-146.1%	-73.7%	-9.2%	1.01×	0.25×	0×	4.72×	0.0%	1	7.23	1	D+
OCGNOcugen, Inc.	$0.94	-5.87×	-33.31×	91.83×	-6.97×	-126.5%	45.9%	-1425.7%	-1537.4%	557.7%	-278.6%	-14.1%	-2.72×	-0.24×	-12.13×	1.06×	0.0%	2	-6.2	2	C
Peer median	—	-6.47×	9.45×	12.73×	-6.97×	-132.8%	75.1%	-17.1%	-37.0%	-28.6%	-73.7%	-9.2%	0.21×	0.25×	0×	4.69×	0.0%	2	1.85	1	—